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Summary
Patients with atopic dermatitis (AD) have an increased risk of bacterial skin infec-
tions, which cause significant morbidity and, if untreated, may become systemic.
Staphylococcus aureus colonizes the skin of most patients with AD and is the most
common organism to cause infections. Overt bacterial infection is easily recog-
nized by the appearance of weeping lesions, honey-coloured crusts and pustules.
However, the wide variability in clinical presentation of bacterial infection in AD
and the inherent features of AD – cutaneous erythema and warmth, oozing asso-
ciated with oedema, and regional lymphadenopathy – overlap with those of
infection, making clinical diagnosis challenging. Furthermore, some features may
be masked because of anatomical site- and skin-type-specific features, and the
high frequency of S. aureus colonization in AD makes positive skin swab culture
of suspected infection unreliable as a diagnostic tool. The host mechanisms and
microbial virulence factors that underlie S. aureus colonization and infection in AD
are incompletely understood. The aim of this article is to present the latest evi-
dence from animal and human studies, including recent microbiome research, to
define the clinical features of bacterial infections in AD, and to summarize our
current understanding of the host and bacterial factors that influence microbial
colonization and virulence.
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Patients with atopic dermatitis (AD; also known as ‘atopic
eczema’) have an increased risk of recurrent skin infections.1–4
Staphylococcus aureus is the most common infectious organ-
ism, although beta-haemolytic streptococci may also be
involved.5–8
The mechanisms underlying bacterial infection in AD are
multifactorial and include both host and bacterial factors. The
reduced skin barrier, cutaneous innate and adaptive immune
abnormalities and trauma from scratching all contribute to the
increased risk of skin infection.9–13 The host skin microbiota
may play a role in protecting against S. aureus colonization and
infection in patients with AD.14–17 Bacterial virulence factors,
such as the superantigens, proteases and cytolytic phenol-solu-
ble modulins (PSMs) secreted by S. aureus, cause skin inflam-
mation and may also contribute to bacterial persistence and/
or epithelial penetration and infection.12,18,19
The complex interaction between bacteria and host results
in wide variability in the clinical presentation of infection in
AD and can make the diagnosis challenging. Cutaneous infec-
tion may be associated with concomitant AD flares, and the
classic signs of infection (erythema, oozing and crusting and
increased cutaneous warmth) are masked by similar clinical
features of AD itself. Increases in erythema in individuals with
darker skin types are more difficult to appreciate, making
diagnosis yet more challenging. Pustules are an uncommon
sign of bacterial infection in AD, but if present they can allow
the diagnosis to be made with greater certainty. Diagnosis and
management decisions are further complicated by the fact that
the main causative organism, S. aureus, commonly colonizes
even nonlesional, clinically unaffected AD skin, thus limiting
the usefulness of bacterial cultures in identifying the causative
organism.
Untreated bacterial skin infection in AD may become sys-
temic and lead to life-threatening complications including sep-
sis, endocarditis and bone and joint infections.20–22 Despite
the significant morbidity caused by bacterial skin infection in
AD, there is a lack of consensus on how to define and treat
associated bacterial colonization and infection. Although there
are many diagnostic criteria for AD itself, there are no vali-
dated diagnostic criteria for infected AD.23
The International Eczema Council, a group of approximately
100 experts in AD worldwide, has recently initiated a task-
force to define the role of bacterial skin infections and their
management in AD through consensus statements in an effort
to provide level D evidence. It is hoped that input from clini-
cal experts will contribute to better defining the wide-ranging
clinical presentations of S. aureus infection in AD and, more
importantly, to identify better those who may benefit from
existing or novel antimicrobial treatments. Based on a system-
atic search of the literature, including terms for AD and ‘infec-
tion’, ‘bacteria’, ‘staphylococcus aureus’ and ‘microbiome’
(detailed search strategy available on request), this narrative
review defines the clinical features of bacterial infection in AD
and our current understanding of the host and bacterial factors
that influence microbial colonization and virulence.
Clinical features of bacterial skin infection in
atopic dermatitis
The typical clinical signs of overt bacterial skin infection in
AD are well recognized. More specific signs of S. aureus infec-
tion in AD lesions include weeping, honey-coloured crusts,
and pustules, both interfollicular and follicular based (folliculi-
tis) (Fig. 1a, b).6,24 Pustules are an uncommon feature of
infection in AD, but may be associated with significant pruri-
tus and even pain (Fig. 1c).25 By contrast, beta-haemolytic
streptococcal infection may present with well-defined, bright
red erythema, thick-walled pustules and heavy crusting
(Fig. 1d).7,26 In severe cases, cutaneous bacterial infection
may cause abscesses – especially with methicillin-resistant
S. aureus (MRSA) infection – fever and lymphadenopathy. A
complication in diagnosing infection in AD is the common
association with a disease flare. Features of flared AD
(increased erythema, oedema, papulation, oozing and excoria-
tion) can mask and/or resemble signs of infection.
Concomitant viral infection
Several nonbacterial infections can occur concomitantly with
bacterial skin infection and can resemble bacterial infections,
requiring consideration in the differential diagnosis. For
instance, eczema herpeticum (EH) is caused by the local
spread of herpes simplex virus, which favours AD lesional skin
and is commonly observed in the context of an AD flare.27
Early in the course of EH the characteristic skin lesions are
superficial clusters of dome-shaped vesicles and/or small,
round, punched-out erosions (Fig. 2a, b).27 As the disease
progresses, lesions may become superficially infected with
S. aureus and may develop an impetiginized scale (Fig. 2c,
d).12 EH typically arises in involved AD skin, most frequently
on the face, neck, upper trunk and antecubital/popliteal areas
with AD, and is often accompanied by fever, malaise and lym-
phadenopathy.28,29 Moderate-to-severe AD, filaggrin loss-of-
function mutation, a history of S. aureus skin infection, greater
allergen sensitization and type 2 immunity are important risk
factors for EH.30–32 Staphylococcal a-toxin and reductions in
the tight junction protein claudin-1 result in greater epidermal
spread of herpes simplex virus in vitro.33,34 This infection can
spread rapidly and, in severe cases, may lead to keratoconjunc-
tivitis and encephalitis.
Concomitant fungal colonization
Fungal colonization can also complicate the clinical picture of
AD. For instance, Malassezia colonization is thought to drive
inflammation in AD in a subset of patients who typically have
dermatitis in areas with a high density of sebaceous glands
(e.g. head, neck, and upper chest and back) (Fig. 3). This seb-
orrhoeic distribution overlaps with, but is distinct from, the
distribution of allergic contact dermatitis or airborne allergy,
which typically involve the upper face, eyelids and periorbital
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regions, anterior neck, postauricular area and exposed areas
on the arms. Malassezia is a commensal yeast. Although it is not
more abundant on AD skin,35 patients with AD are more fre-
quently sensitized to Malassezia.36–38 In some patients, sensitiza-
tion to yeast antigens induces autoreactivity to human proteins
via molecular mimicry, leading to sustained skin inflamma-
tion.39,40 Cross-reactivity between Malassezia-specific IgE and
Candida albicans has also been shown.41 A systematic review of
the eight published randomized controlled trials evaluating the
benefit of antifungal therapy found that five trials demon-
strated a benefit from antifungal drugs and three trials found
no benefit compared with placebo or standard therapy.38
Bacterial skin infection in different ethnic skin
types
There is wide variation in the clinical manifestation of AD in
different ethnic groups. This may be a result of underlying
genetic variation, which influences AD susceptibility and clini-
cal presentation, inadequate early intervention because of
masking of erythema in dark skin, and differences in both
treatment response and environmental exposures.42 In dark-
skinned individuals, perifollicular accentuation is often present
and erythema appears violaceous and often muted (Fig. 4).43–45
This can lead to poor recognition of inflammation, underes-
timation of disease severity and inadequate intervention.
Patients with AD of African descent often have extensor dis-
ease rather than the characteristic flexural lesions.45 Impor-
tantly, S. aureus strain differences, including variability in the
presence of superantigen genes, has been shown between
European American, African American and Mexican American
patients with AD.46
Methicillin-resistant Staphylococcus aureus
As in healthy people who are colonized by MRSA, patients
with AD often have recurrent infections and disease flares
that are resistant to standard treatment regimens (Fig. 5).
The prevalence of MRSA skin colonization varies significantly
with geographical location and study setting in both healthy
and diseased populations. It is therefore difficult to compare
accurately the prevalence of MRSA colonization between AD
and healthy cohorts. For example, in the U.S.A. there is
significant state-wide variation, with the rate of MRSA colo-
nization varying between 03% and 13% in people with
AD.3,47–49 In another study, 4–19% of children with AD
from the U.K. and Ireland were found to be colonized with
MRSA.50,51 The reported prevalence of MRSA colonization in
(a) (c)
(b) (d)
Fig 1. Clinical features of bacterial skin infection in atopic dermatitis. Clinical features of S. aureus infection in atopic dermatitis lesions include (a)
weeping, honey-coloured crusts; (b) folliculitis; and (c) pustulation. (d) Beta-haemolytic streptococcal infection may present with well-defined
bright red erythema.
© 2019 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists
British Journal of Dermatology (2020) 182, pp1331–1342
The role of bacterial skin infections in atopic dermatitis, H. Alexander et al. 1333
patients with AD in Sri Lanka is 8%, and in Korea 3–
14%.52–55 A meta-analysis of MRSA colonization in the gen-
eral population reported a prevalence of 02–7% world-
wide.56 The authors describe significant study heterogeneity.
In a subgroup analysis that excluded people with prior
healthcare contact, the prevalence of MRSA colonization was
found to be very low (02%).
Although some studies suggest that MRSA colonization rates
are higher in people with AD than in the general population,
other studies have found much lower rates. For instance, a
cross-sectional study of 200 patients with AD in Canada found
MRSA in only one individual.57 Similarly, children with AD
from San Diego were found to have a lower rate of commu-
nity-acquired MRSA colonization than the general outpatient
paediatric population.58 Further research is needed to under-
stand the significance of MRSA in AD.
Staphylococcus aureus colonization in atopic
dermatitis
Most patients with AD are colonized by S. aureus. A recent
meta-analysis found that the pooled prevalence of S. aureus col-
onization of lesional AD skin is 70%, of nonlesional AD skin
39% and of the nares 62%.59 However, the prevalence varies
greatly across studies, from 22% to 99% in lesional skin and
3% to 79% in nonlesional skin.59–63 Most patients colonized
by S. aureus do not exhibit overt signs of infection, and 10% of
healthy individuals carry S. aureus.62,64
Staphylococcus aureus colonization can be associated with three
main clinical scenarios in AD: (i) stable or baseline AD with-
out clinical evidence of overt infection; (ii) AD flare without
(a)
(c)
(b)
(d)
Fig 2. Clinical features of eczema herpeticum. (a, b) Early eczema herpeticum lesions are superficial clusters of dome-shaped vesicles and/or
small, round, punched-out erosions. (c, d) As the disease progresses, the lesions commonly become superficially infected with Staphylococcus aureus
and may have the characteristic impetiginized scale.
Fig 3. Malassezia colonization in atopic dermatitis, which may drive
inflammation in patients who have head and neck dermatitis.
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clinical evidence of overt infection; and (iii) overtly infected
AD with the classical symptoms as described above. Although
antimicrobial therapy is clearly essential for patients with
overtly infected AD, the clinical significance, recognition and
management of S. aureus colonization without clinical evidence
of infectious disease are not fully understood. Some studies
show that patients with AD improve with topical and systemic
antibiotic treatments, even without overt signs of secondary
infection.65–70 However, other studies have found no clinical
benefit of antibiotic treatment over corticosteroid therapy
alone.63,71 A 2010 Cochrane review found no support for
routine topical or systemic antistaphylococcal interventions in
AD that is not clinically infected, although the studies were
generally short term and of poor quality.72
It is likely that the density of S. aureus is more relevant than
simply the presence of the bacteria. The density of S. aureus
colonization correlates with the severity of AD.73–76 Wil-
liamson and Kligman used an early method of quantitative
bacteriology to compare the effects of topical and systemic
antibiotics on S. aureus in AD.77 The detergent scrub technique
was used on AD lesions to obtain bacterial samples, which
were incubated before the S. aureus density was measured. They
found that appreciable clinical improvement with antibiotic
therapy occurred only in patients whose AD lesions were
infected by S. aureus at a density of greater than 106 colony-
forming units per cm2.61,68 Similarly, microbiome studies of
paediatric patients with AD show that the relative abundance
of S. aureus is associated with disease flares and correlates with
severity.78–81
In addition to bacterial abundance, there are several addi-
tional factors that determine whether S. aureus successfully col-
onizes the skin in AD and whether this results in clinically
relevant infection. Casadevall and Pirofski described the
‘damage–response framework’ approach to microbial patho-
genesis.82,83 The basic tenets of this concept are that host and
microbe interact to create a spectrum of possible states, rang-
ing from commensalism and colonization to disease. Disease
results from damage to the host, which can come from the
host response, the microbe or both. The damage–response
framework defines infection as the acquisition of a microbe,
but it does not necessarily mean the microbe is causing dis-
ease. Infection results in disease when the host–microbe inter-
action produces sufficient damage to become clinically
apparent.84
This approach is a framework that advances thinking
beyond the classic microbe-centric Koch’s postulates that
dominated microbiological thought for more than a century.
(a)
(d) (f)(e)
(b) (c)
Fig 4. Atopic dermatitis in different ethnic skin types. In dark-skinned individuals perifollicular accentuation is often present in atopic dermatitis,
and erythema appears violaceous.
Fig 5. Methicillin-resistant Staphylococcus aureus infection in atopic
dermatitis may cause recurrent flares that are resistant to standard
treatment regimens.
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It may be a useful approach for understanding the S. aureus–
host interaction in AD and the range of clinical scenarios that
can arise (Fig. 6). We have some understanding of the vari-
ous bacterial and host factors that contribute during S. aureus
infection in AD. However, the key questions to be answered
are (i) which of these factors lead to worsening inflamma-
tion in AD? and (ii) can a threshold of host damage result-
ing from the S. aureus–host interaction be defined, beyond
which antibiotics prove beneficial? If the key host and
microbial factors that determine these outcomes are identi-
fied, then targeting of these specific factors with novel
immunotherapies or selective antimicrobial therapies may
become a reality.14,85
Host factors associated with Staphylococcus
aureus colonization
Adults with AD who are colonized with S. aureus have more
severe disease, and greater T helper type 2 (Th2) immune
deviation, allergen sensitization and barrier dysfunction than
noncolonized patients with AD.86 Some studies have found
that filaggrin mutations are associated with S. aureus coloniza-
tion in AD, but others have not.86–88 The increased suscepti-
bility to S. aureus colonization and infection in AD is
multifactorial and driven by both skin barrier abnormalities
and innate and adaptive immune responses (Fig. 7).
The impaired skin barrier
The impaired skin barrier in AD is characterized by reduced
very-long-chain epidermal lipids, defective tight junctions, dif-
ferentiation in protein deficiency (including from filaggrin
loss-of-function mutations), enhanced protease activity and
increased skin-surface pH. This impaired barrier provides a
favourable environment for S. aureus colonization.89–92 The
deposition of stratum corneum (SC) fibronectin, to which
S. aureus adheres, is increased in AD.26,93,94 Staphylococcus aureus
clumping factor B binds to loricrin and cytokeratin 10 and
promotes adhesion of S. aureus to the stratum corneum in
AD.95 Antimicrobial peptides (AMPs) such as b-defensins and
cathelicidins are also reduced in AD lesions.96
Type 2 inflammation
Type 2 inflammatory pathways, in which the cytokines inter-
leukin (IL)-4 and IL-13 play a major role, drive inflammation
in AD. Th2 cytokines reduce expression of important skin bar-
rier proteins: filaggrin, loricrin and involucrin.97,98 The
expression of fibronectin is increased by IL-4 and may facili-
tate S. aureus adherence in AD.99 The failure to mount an
appropriate AMP response in AD may also be due to the sup-
pressive effects of IL-4 and IL-13, and may enhance S. aureus
colonization further.12,13,100
A recent pooled analysis of seven randomized, placebo-con-
trolled dupilumab trials in adults with moderate-to-severe AD
found that bacterial skin infections were significantly less com-
mon in the dupilumab groups than in the placebo group.101
Similarly, a meta-analysis of data from eight dupilumab trials
found that patients treated with dupilumab had a lower risk
of skin infection than those treated with placebo.102 The
reduced rate of skin infection with dupilumab supports the
role of a Th2-driven host skin barrier defect in infection in
AD, which after treatment may become a less favourable envi-
ronment for bacteria. This shift may be mediated by inhibition
Fig 6. Hypothetical damage–response framework for Staphylococcus aureus in atopic dermatitis (AD).82 Different host–S. aureus interactions result in
different damage–response relationships. Curves A and B represent the damage–response relationships of S. aureus with two different hosts or those
of a single host with two different S. aureus strains. The outcome for the host depends on the strength of the host response to S. aureus or the
virulence of S. aureus. During intermediate host responses neither interaction (A or B) causes clinical evidence of infection, as the amount of
damage incurred by the host is insufficient (1). However, in the setting of weak or strong responses both interactions cause an AD flare (2) and
interaction B causes overtly infected AD (3). The position of the curve is determined by multiple host and S. aureus factors.
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of type 2 inflammatory cytokines, reduced scratching, or
microbiome changes induced by dupilumab. Dupilumab treat-
ment results in increased microbial diversity and decreased
S. aureus abundance in AD.103
The skin microbiome
Microbial diversity is reduced in AD and inversely correlates
with disease severity.78,79,81 Skin commensal microbes,
including coagulase-negative staphylococci (CoNS), may aid
skin homeostasis and provide protection against S. aureus. Thus,
the diminution of commensal skin microbiota with flares may
promote S. aureus colonization and infection in AD. During
flares of paediatric AD, both Staphylococcus epidermidis and S. aureus
are increased, suggesting a compensatory role for S. epider-
midis.78 This skin commensal promotes AMP expression by cul-
tured keratinocytes via Toll-like receptor 2 signalling.104
Furthermore, S. epidermidis produces PSMc and PSMd, which
enhance AMP effects and inhibit growth of S. aureus and group
A Streptococcus in vitro.105 Cutaneous application of antimicrobial
CoNS strains to adults with AD decreased colonization by
S. aureus within 24 h of a single application.14
In addition to inhibiting S. aureus colonization, CoNS also
reduce S. aureus-driven skin inflammation. CoNS from healthy
skin produce autoinducing peptides that inhibit the S. aureus
accessory gene regulatory quorum sensing system, leading to
reduced expression of the S. aureus virulence factor PSMa
in vitro and reduced S. aureus-induced skin barrier damage in
mice.16 Cutibacterium acnes supresses growth of MRSA in mouse
skin through glycerol fermentation, leading to short-chain
fatty acid production and reduced bacterial intracellular pH.15
Treatment with the Gram-negative Roseomonas mucosa, collected
from healthy human skin, inhibits the growth of S. aureus
in vitro and results in reduced inner-ear thickness in a mouse
Fig 7. Possible mechanisms of Staphylococcus aureus colonization and virulence in atopic dermatitis (AD). Staphylococcus aureus colonization is increased
in AD skin. This may be due to epidermal barrier dysfunction, reduced levels of antimicrobial peptides (AMPs), reduced microbial diversity or
increased fibrinogen and fibronectin. Proteases produced by the host and S. aureus allow the bacteria to penetrate into the deeper layers of the skin.
Staphylococcal enterotoxins (SEs) stimulate polyclonal T-cell responses, SE-specific IgE responses and interleukin (IL)-31 expression. a-Toxin can
cause keratinocyte death and can activate keratinocyte IL-1a and IL-36a production to stimulate cdT cells, innate lymphoid cell (ILC)-3-mediated
IL-17 release and neutrophil (Neut) recruitment. d-Toxin causes mast cell (MC) degranulation. Staphylococcal protein A (SpA) activates
proinflammatory pathways via tumour necrosis factor receptor 1 (TNFR1) on keratinocytes. Staphylococcus aureus lipoteichoic acid (LTA) and
lipoproteins activate Toll-like receptor (TLR)2 and TLR6 to produce thymic stromal lymphopoietin (TSLP), which activates dendritic cells (DC)
and ILC-2, leading to production of T helper cell (Th)2 cytokines.
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model of AD.106 In human studies, spraying R. mucosa onto
lesional AD skin of the antecubital area improved AD severity
and reduced the need for topical corticosteroids.17 MRSA colo-
nization is associated with reduced microbial diversity com-
pared with methicillin-sensitive S. aureus colonization of AD
lesional skin and greater decreases in the relative abundance of
skin commensal bacteria, including Cutibacterium, Streptococcus
and Corynebacterium.47 Further research is needed to understand
the interactions between S. aureus and commensal organisms,
and how these organisms relate to host immune responses.
Staphylococcus aureus factors promoting
colonization and virulence
Staphylococcus aureus exacerbates AD by secreting virulence factors
that affect the epidermis (leading to inflammation and skin
barrier disruption) and factors that hamper innate and adap-
tive immune responses (Fig. 7). Staphylococcal superantigens
activate polyclonal T-cell responses without prior antigen pro-
cessing and by activating epithelial cells via CD40.107–109 Sev-
eral of the staphylococcal enterotoxins can also act as allergens
to stimulate staphylococcal exotoxin-specific IgE produc-
tion.110 Staphylococcal enterotoxin B increases the expression
of IL-31, which is well known to cause pruritus in AD.111 IL-31
also suppresses filaggrin and AMP expression, resulting in
increased S. aureus colonization.112,113 Superantigen-producing
strains are found in over 80% of S. aureus isolates from
patients with AD.114 MRSA produces higher levels of super-
antigen enterotoxins than methicillin-sensitive S. aureus.115
Additional toxins such as the staphylococcal PSMs, including
d-toxin and a-toxin, may additionally enhance the virulence of
S. aureus in AD. The d-toxin is a potent inducer of mast cell
degranulation in vitro and in mouse models of AD.116 a-Toxin
treatment of AD skin causes keratinocyte death, which is
enhanced by IL-4 and IL-13.117 Recent studies have shown that
a-toxin activates keratinocyte IL-1a and IL-36a production,
which stimulates cdT cells, innate lymphoid cell (ILC)-
3-mediated IL-17 release and neutrophil recruitment.118,119
Filaggrin protects keratinocytes by mediating the secretion of
sphingomyelinase, an enzyme that reduces the number of
a-toxin binding sites on the keratinocyte surface.120 Staphylococcus
aureus growth and virulence factor production are reduced in the
presence of filaggrin breakdown products.121 These studies
suggest that S. aureus-produced mediators potentiate the effects
of S. aureus in AD, and filaggrin-deficient epidermis may be
particularly susceptible to S. aureus.
Staphylococcal protein A activates proinflammatory path-
ways via tumour necrosis factor receptor 1 on ker-
atinocytes.122 Staphylococcus aureus lipoteichoic acid and
lipoproteins activate Toll-like receptors 2 and 6 to exacerbate
AD and stimulate release of thymic stromal lymphopoietin
(TSLP) from keratinocytes. TSLP activates dendritic cells and
ILC-2, leading to further production of type 2 cytokines.12,123
Staphylococcus aureus proteases are required for penetration of the
bacteria into the deeper layers of the skin and the induction
of Th2 cytokine production.124 Staphylococcus aureus also
stimulates keratinocytes to increase their endogenous protease
activity.125 Whole-genome sequencing of S. aureus has recently
revealed higher levels of antimicrobial resistance genes in
S. aureus isolates from children with AD than in those from
healthy control children, suggesting additional potential S. aur-
eus virulence mechanisms in AD.52,126
Conclusions
Bacterial infection in AD is common and causes significant
morbidity. Overt bacterial infection is easily recognized. How-
ever, less overt manifestation of infection may be more diffi-
cult to diagnose, especially given the greater risk of infection
with flares (themselves associated with increased erythema
and oozing), as well as the limited value of culture, given the
high rates of colonization. Although we have some under-
standing of how S. aureus colonizes the skin and causes inflam-
mation in AD, many questions related to this complex
relationship remain unanswered. Further research is needed
for better definition of features that distinguish infection from
colonization. Future work of the International Eczema Council,
through expert consensus statements, aims to provide guid-
ance regarding the practical use of antimicrobial therapy in
atopic dermatitis. Improving our understanding of S. aureus vir-
ulence mechanisms and downstream host immune mediators
of S. aureus-driven inflammatory pathways may help to identify
novel therapeutic targets for infection in AD.
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